Home > Healthcare > Pharmaceuticals > Finished Drug Form > Methicillin-resistant Staphylococcus Aureus Drugs Market
Methicillin-resistant Staphylococcus Aureus Drugs Market Size
- Report ID: GMI9303
- Published Date: Apr 2024
- Report Format: PDF
Methicillin-resistant Staphylococcus Aureus Drugs Market Size
Methicillin-Resistant Staphylococcus Aureus Drugs Market size was valued at USD 4.1 billion in 2023 and is anticipated to grow at a CAGR of 4.2% between 2024 – 2032. One of the primary drivers is the increasing prevalence of MRSA infections globally, particularly in healthcare settings.
Additionally, rising cases of antibiotic resistance, further drives the market growth. For instance, as per the CDC's 2019 Antibiotic Resistance (AR) Threats Report, more than 2.8 million antimicrobial-resistant infections occur each year, resulting in more than 35,000 deaths in the U.S. Moreover, rising awareness about the seriousness of MRSA infections among healthcare providers and patients is driving the demand for effective treatment options. Furthermore, the growing research and development activities in the field of antimicrobial agents, along with the development of novel therapies targeting MRSA, are expected to contribute to market growth.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Methicillin-resistant Staphylococcus Aureus Drugs Market Size in 2023: | USD 4.1 Billion |
| Forecast Period: | 2024 - 2032 |
| Forecast Period 2024 - 2032 CAGR: | 4.2% |
| 2032 Value Projection: | USD 5.9 Billion |
| Historical Data for: | 2021 - 2023 |
| No. of Pages: | 190 |
| Tables, Charts & Figures: | 333 |
| Segments covered: | Drug Class, MRSA Type, Route of Administration, Indication, Distribution Channel, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Methicillin-resistant staphylococcus aureus (MRSA) drugs are medications specifically designed to treat infections caused by Staphylococcus aureus bacteria that have developed resistance to methicillin and other commonly used antibiotics. MRSA infections can range from mild skin infections to more severe and potentially life-threatening infections such as pneumonia and bloodstream infections.
Frequently Asked Questions (FAQ) :
Methicillin-resistant Staphylococcus Aureus Drugs Market Scope
